Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection: A propensity score–matched retrospective cohort study
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection: A propensity score–matched retrospective cohort study
Authors
Keywords
COVID-19, CT-P59, Pneumonia, Outcome
Journal
INTERNATIONAL IMMUNOPHARMACOLOGY
Volume 106, Issue -, Pages 108570
Publisher
Elsevier BV
Online
2022-02-04
DOI
10.1016/j.intimp.2022.108570
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- COVID-19 vaccines: where we stand and challenges ahead
- (2021) Guido Forni et al. CELL DEATH AND DIFFERENTIATION
- Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19
- (2021) Robert L. Gottlieb et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein
- (2021) Cheolmin Kim et al. Nature Communications
- A Cost-Effectiveness Framework for COVID-19 Treatments for Hospitalized Patients in the United States
- (2021) Daniel Sheinson et al. ADVANCES IN THERAPY
- Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials
- (2021) Ahmad Al-Abdouh et al. Contemporary Clinical Trials
- A mobile unit overcomes the challenges to monoclonal antibody infusion for COVID ‐19 in skilled care facilities
- (2021) Sidna Tulledge‐Scheitel et al. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
- Cost-effectiveness of Remdesivir and Dexamethasone for COVID-19 Treatment in South Africa
- (2021) Youngji Jo et al. Open Forum Infectious Diseases
- India's COVID-19 emergency
- (2021) The Lancet LANCET
- Impact of bamlanivimab monoclonal antibody treatment on hospitalization and mortality among non-hospitalized adults with SARS-CoV-2 infection
- (2021) J Ryan Bariola et al. Open Forum Infectious Diseases
- Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19
- (2021) Brian T. Garibaldi et al. JAMA Network Open
- Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant
- (2021) Dong-Kyun Ryu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection
- (2021) Jin Yong Kim et al. CLINICAL THERAPEUTICS
- Count the cost of disability caused by COVID-19
- (2021) Andrew Briggs et al. NATURE
- Treatment of moderate to severe respiratory COVID-19: a cost-utility analysis
- (2021) Stephen E. Congly et al. Scientific Reports
- Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1–August 1, 2021
- (2021) Srinivas Nanduri et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Real-world Effect of Monoclonal Antibody Treatment in COVID-19 Patients in a Diverse Population in the United States
- (2021) Kaitlin Rainwater-Lovett et al. Open Forum Infectious Diseases
- The Relevance of Monoclonal Antibodies in the Treatment of COVID-19
- (2021) Anabel Torrente-López et al. Vaccines
- Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
- (2021) Sara Y Tartof et al. LANCET
- Effectiveness of Regdanvimab Treatment in High-Risk COVID-19 Patients to Prevent Progression to Severe Disease
- (2021) Ji Yeon Lee et al. Frontiers in Immunology
- 546. Therapeutic Effect of Regdanvimab in Patients with Mild to Moderate COVID-19: Day 28 Results from a Multicentre, Randomised, Controlled Pivotal Trial
- (2021) Michael G Ison et al. Open Forum Infectious Diseases
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- (2020) Markus Hoffmann et al. CELL
- Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area
- (2020) Safiya Richardson et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A human neutralizing antibody targets the receptor binding site of SARS-CoV-2
- (2020) Rui Shi et al. NATURE
- A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2
- (2020) Yan Wu et al. SCIENCE
- Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
- (2020) Lihong Liu et al. NATURE
- Potently neutralizing and protective human antibodies against SARS-CoV-2
- (2020) Seth J. Zost et al. NATURE
- Adapting hospital capacity to meet changing demands during the COVID-19 pandemic
- (2020) Ruth McCabe et al. BMC Medicine
- Policies and innovations to battle Covid-19 – A case study of South Korea
- (2020) Doowon Lee et al. Health Policy and Technology
- Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
- (2020) David M. Weinreich et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
- (2020) Peter Chen et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now